Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study

IMPORTANCE: Patients with EGFR mutations who have advanced-stage non-small cell lung cancer (NSCLC) already receive tyrosine kinase inhibitors (TKIs) as the standard first-line therapy. Notably, Yunnan is a regional high incidence area of lung cancer in the highlands with a high rate of rare EGFR mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yanping, Chen, Long, Li, Rong, Liu, Xin, Li, Quan, Cai, Jingjing, Du, Yaxi, Zhao, Guangqiang, Wang, Xiaoxiong, Shen, Zhenghai, Liao, Yedan, Chen, Yang, Xie, Lin, Zhou, Yongchun, Huang, Yunchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597689/
https://www.ncbi.nlm.nih.gov/pubmed/37881485
http://dx.doi.org/10.3389/fonc.2023.1156647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597689/
https://www.ncbi.nlm.nih.gov/pubmed/37881485
http://dx.doi.org/10.3389/fonc.2023.1156647

Ejemplares similares